Author(s)

Manuela Machado¹, Maria Leitão¹, Mário Fontes e Sousa², Magalhães e Helena³

¹Oncologia Médica, IPO Porto, Porto, Portugal.
²Oncologia Médica, Centro Hospitalar Lisboa Ocidental (CHLO), Lisboa, Portugal.
³Oncologia Médica, Unidade Local de Saúde de Matosinhos, Hospital Pedro Hispano, Matosinhos, Portugal.

Pancreatic adenocarcinoma is currently a major public health problem, being the 7th cause of death worldwide. Incidence is increasing and unfortunately nowadays the incidence is almost overlapping to mortality. The cornerstone of curative treatment is still surgery, but adjuvant treatment is critical to decreasing the risk of recurrence.

Pancreatic Adenocarcinoma, Adjuvant Chemotherapy, Positive Clinical Trials

Machado, M. , Leitão, M. , e Sousa, M. and e Helena, M. (2019) A New Era in the Adjuvant Treatment of Pancreatic Adenocarcinoma. Journal of Cancer Therapy, 10, 915-919. doi: 10.4236/jct.2019.1012078.